| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/2159-8290.CD-12-0028 |
| P698 | PubMed publication ID | 22705984 |
| P50 | author | Choon Kiat Ong | Q40793543 |
| Bin Tean Teh | Q47451223 | ||
| P2093 | author name string | Patrick Tan | |
| Soo Yong Tan | |||
| Soon Thye Lim | |||
| Christopher Goh | |||
| Tiffany Tang | |||
| Kheng-Wei Yeoh | |||
| Ioana Cutcutache | |||
| Steve Rozen | |||
| George E Allen | |||
| Whee Sze Ong | |||
| Leonard Tan | |||
| Miriam Tao | |||
| Richard Quek | |||
| Susan Loong | |||
| Swee Peng Yap | |||
| Daryl Tan | |||
| Kevin Tay | |||
| Cedric Chuan Young Ng | |||
| Vikneswari Rajasegaran | |||
| Song Ling Poon | |||
| Lay Cheng Lim | |||
| Hong Lee Heng | |||
| Kuo Ann Lee | |||
| Ghee Chong Koo | |||
| Anna Gan | |||
| Willie Yu | |||
| Soo Ching Chong | |||
| P433 | issue | 7 | |
| P304 | page(s) | 591-597 | |
| P577 | publication date | 2012-06-15 | |
| P1433 | published in | Cancer Discovery | Q15724440 |
| P1476 | title | Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma | |
| P478 | volume | 2 |
| Q90812985 | A clinicohaematological prognostic model for nasal-type natural killer/T-cell lymphoma: A multicenter study |
| Q38724665 | A neutralized human LMP1-IgG inhibits ENKTL growth by suppressing the JAK3/STAT3 signaling pathway |
| Q43135354 | A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy |
| Q92262684 | Activated hippo signal pathway inhibits cell proliferation and promotes apoptosis in NK/T cell lymphoma cells |
| Q54342283 | Activated janus kinase 3 expression not by activating mutations identified in natural killer/T-cell lymphoma. |
| Q42827073 | Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells |
| Q33718415 | Adapter protein Shc regulates Janus kinase 3 phosphorylation |
| Q59793939 | Advances in multiple omics of natural-killer/T cell lymphoma |
| Q90482750 | Advances in targeted therapy for malignant lymphoma |
| Q47113632 | Advances in the understanding and management of T-cell prolymphocytic leukemia |
| Q52718168 | Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. |
| Q43905021 | Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis |
| Q57216715 | Aspects moléculaires des lymphomes T périphériques (2) |
| Q41721837 | Association between extranodal natural killer/T-cell lymphoma and hepatitis B viral infection: a case-control study |
| Q40040761 | Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease |
| Q91187938 | Characteristic gene alterations in primary gastrointestinal T- and NK-cell lymphomas |
| Q40766488 | Coexistence of systemic lupus erythematosus, tuberous sclerosis and aggressive natural killer-cell leukaemia: coincidence or correlated? |
| Q35832062 | Concurrent Mutations in ATM and Genes Associated with Common γ Chain Signaling in Peripheral T Cell Lymphoma |
| Q54982413 | Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies. |
| Q30275203 | Cutaneous EBV-related lymphoproliferative disorders |
| Q38868306 | Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations |
| Q59359829 | Defining the elusive boundaries of chronic active Epstein-Barr virus infection |
| Q38763094 | Development of Selective Covalent Janus Kinase 3 Inhibitors. |
| Q30249309 | Diagnosis and management of extranodal NK/T cell lymphoma nasal type. |
| Q38201143 | Disease-specific mutations in mature lymphoid neoplasms: recent advances |
| Q39107367 | Downregulation of miR-15a due to LMP1 promotes cell proliferation and predicts poor prognosis in nasal NK/T-cell lymphoma |
| Q38761793 | EBV-negative aggressive NK-cell leukemia/lymphoma: a clinical and pathological study from a single institution |
| Q44028421 | Effect of Janus kinase 3 on the peptide transporters PEPT1 and PEPT2. |
| Q35132241 | Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies |
| Q90012509 | Epigenetic aberrations in natural killer/T-cell lymphoma: diagnostic, prognostic and therapeutic implications |
| Q64039644 | Epstein-Barr Virus-Associated T and NK-Cell Lymphoproliferative Diseases |
| Q64269086 | Epstein-Barr Virus-Positive Natural Killer/T-Cell Lymphoma |
| Q56930876 | Epstein-Barr virus-associated lymphomas |
| Q45328020 | Epstein-Barr virus-negative extranodal "true" natural killer-cell lymphoma harbouring a KDM6A mutation. |
| Q44998179 | Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia |
| Q40717160 | Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma |
| Q40101543 | Frequent BCOR aberrations in extranodal NK/T-Cell lymphoma, nasal type |
| Q38186617 | From empiric to mechanism-based therapy for peripheral T cell lymphoma. |
| Q39183278 | Genetic Landscape and Classification of Peripheral T Cell Lymphomas |
| Q36232164 | Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type |
| Q40596015 | Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. |
| Q92265373 | Genetic susceptibility to natural killer T-cell lymphoma |
| Q91136332 | Genomic analysis reveals recurrent deletion of JAK-STAT signaling inhibitors HNRNPK and SOCS1 in mycosis fungoides |
| Q90463789 | Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma |
| Q39237403 | HiJAKing the epigenome in leukemia and lymphoma |
| Q89725109 | IL-9 and Th9 Cells in Tumor Immunity |
| Q33798544 | Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia |
| Q34106849 | Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia |
| Q26782539 | JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications |
| Q39142126 | JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics |
| Q39149556 | JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. |
| Q64120387 | JAK3/STAT3 oncogenic pathway and PRDM1 expression stratify clinicopathologic features of extranodal NK/T‑cell lymphoma, nasal type |
| Q34321767 | JAKs and STATs in immunity, immunodeficiency, and cancer |
| Q58796912 | LEE011 and ruxolitinib: a synergistic drug combination for natural killer/T-cell lymphoma (NKTCL) |
| Q42330161 | MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia. |
| Q39064213 | Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming |
| Q57287731 | MiRNA-155 regulates lymphangiogenesis in natural killer/T-cell lymphoma by targeting BRG1 |
| Q38191876 | Modes of infection and oncogenesis by the Epstein-Barr virus. |
| Q89304773 | Molecular Insights Into Pathogenesis of Peripheral T Cell Lymphoma: a Review |
| Q38597997 | Molecular Pathogenesis of Peripheral T Cell Lymphoma |
| Q64085662 | Molecular pathogenic pathways in extranodal NK/T cell lymphoma |
| Q37708936 | Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. |
| Q47395580 | Mutant JAK3 signaling is increased by loss of wild type JAK3 or by acquiring secondary JAK3 mutations in T-ALL. |
| Q37324841 | Mutational Analysis of Extranodal NK/T-Cell Lymphoma Using Targeted Sequencing with a Comprehensive Cancer Panel |
| Q91855455 | Mutational profile and EBV strains of extranodal NK/T-cell lymphoma, nasal type in Latin America |
| Q37389358 | Mutations in the JAK/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas |
| Q28540834 | NCI-60 whole exome sequencing and pharmacological CellMiner analyses |
| Q39263682 | New tumor entities in the 4th edition of the World Health Organization classification of head and neck tumors: Nasal cavity, paranasal sinuses and skull base. |
| Q47548002 | Novel findings from the Asian Lymphoma Study Group: focus on T and NK-cell lymphomas |
| Q90483988 | Oncogenic Network and Hub Genes for Natural Killer/T-Cell Lymphoma Utilizing WGCNA |
| Q55281964 | Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies. |
| Q50055394 | Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma |
| Q58742961 | Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma |
| Q64087879 | Pathogenesis and biomarkers of natural killer T cell lymphoma (NKTL) |
| Q97645211 | Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK/T-cell lymphoma |
| Q36277681 | Primary CNS T-cell Lymphomas: A Clinical, Morphologic, Immunophenotypic, and Molecular Analysis |
| Q58690869 | Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma |
| Q87538001 | RHOA mutations in peripheral T cell lymphoma |
| Q36259257 | RUNX3 is oncogenic in natural killer/T-cell lymphoma and is transcriptionally regulated by MYC. |
| Q44535044 | Rare occurrence of JAK3 mutations in natural killer cell neoplasms in Japan |
| Q47240802 | Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma |
| Q90134157 | Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma |
| Q52647036 | Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. |
| Q89090594 | Refining pathological diagnoses in lymphoid malignancies |
| Q35067345 | Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas |
| Q59354279 | STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target |
| Q54959839 | STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma. |
| Q35145308 | Serum levels of interleukin-9 correlate with negative prognostic factors in extranodal NK/T-cell lymphoma |
| Q39063866 | T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment |
| Q34648812 | Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib |
| Q60019698 | The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation |
| Q90260574 | The Role of Interleukin-9 in Cancer |
| Q39243241 | The diagnosis and management of NK/T-cell lymphomas. |
| Q47147269 | The effect of the JAK2 inhibitor TG101209 against T cell acute lymphoblastic leukemia (T-ALL) is mediated by inhibition of JAK-STAT signaling and activation of the crosstalk between apoptosis and autophagy signaling |
| Q38741546 | Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells |
| Q42378681 | Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 Inhibitors |
| Q37257158 | Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations |
| Q52899841 | Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Hematolymphoid Tumours. |
| Q27320602 | Using drug response data to identify molecular effectors, and molecular "omic" data to identify candidate drugs in cancer |
| Q38115228 | VIII. New markers in peripheral T-cell lymphomas: more entities or more confusion? |
| Q58695601 | Whole exome sequencing identifies recessive germline mutations in FAM160A1 in familial NK/T cell lymphoma |
| Q38705023 | Whole transcriptome analysis reveals dysregulated oncogenic lncRNAs in natural killer/T-cell lymphoma and establishes MIR155HG as a target of PRDM1. |
| Q35884253 | Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides |
| Q87195954 | [The progress of diagnostic and prognostic molecular markers of lymphoma] |
Search more.